Anna Lübking (Former)
1 – 5 of 12
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry
(
- Contribution to journal › Article
-
Mark
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
(
- Contribution to journal › Article
- 2020
-
Mark
Introducing patient-reported outcome in the acute leukemia quality registries in Sweden
(
- Contribution to journal › Article
- 2018
-
Mark
Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow
(
- Contribution to journal › Letter
- 2017
-
Mark
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
(
- Contribution to journal › Article